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Cellular uptake of metallated cobalamins
Mai Thanh Quynh Tran,†a Stefan Stu¨rup,*b Ian Henry Lambert,c
Bente Gammelgaard,b Evelyne Furger‡d and Roger Alberto*a
Cellular uptake of vitamin B12-cisplatin conjugates was estimated via detection of their metal constituents (Co,
Pt, and Re) by inductively coupled plasma mass spectrometry (ICP-MS). Vitamin B12 (cyano-cob(III)alamin) and
aquo-cob(III)alamin [Cbl-OH2]
+, which diﬀer in the b-axial ligands (CN and H2O, respectively), were included as
control samples. The results indicated that B12 derivatives delivered cisplatin to both cellular cytosol and nuclei
with an eﬃciency of one third compared to the uptake of free cisplatin cis-[PtIICl2(NH3)2]. In addition, uptake of
charged B12 derivatives including [Cbl-OH2]
+, [{Co}-CN-{cis-PtCl(NH3)2}]
+, [{Re}-{Co}-CN-{cis-PtCl(NH3)2}]
+,
and [{Co}-CN-{trans-Pt(Cyt)(NH3)2}]
2+ (Cyt = cytarabin) was high compared to neutral B12, which implied the
existence of an additional internalization pathway for charged B12 vitamin analogs. The aﬃnities of the charged
B12 derivatives to the B12 transporters HC, IF and TC were similar to that of native vitamin B12.
Introduction
Cyano-cob(III)alamin, also designated vitamin B12, is an essential,
water soluble, and non-toxic vitamin even at high doses. Vitamin
B12 is involved in the methionine synthesis and the tricarboxylic
acid cycle. B12 comprises an octahedral CoIII complex with a
tetradentate corrin ring, an a-nucleotide loop and a CN ligand in
the b-axial position. The cyanide ligand can be exchanged for other
monodentate functions (Fig. 1).1 Intracellular reduction of the CoIII
center subsequently forms square pyramidal cob(II)alamin and
square planar cob(I)alamin, respectively.2,3 Enzymatic alkylation of
cob(I)alamin in the cytosol andmitochondria leads to the formation
of two B12-coenzymes withmethyl and adenosyl as b-ligands.4,5 B12
is protected from degradation inside living systems through its
binding to the proteins haptocorrin (HC, present in saliva/
gastric fluids), intrinsic factor (IF, secreted by parietal cells),
and transcobalamin (TC, plasma protein).6,7 Binding of B12 to
TC is required for facilitating the uptake of the B12–TC complex
via the TC-receptor or CD320 (acrossmostmembranes) andmegalin
(reabsorbed from the urine in kidney cells).7 The B12 specificity
follows the order: IF4 TCc HC.8–11 Numerous functional groups
on the corrin side chains, b-ligand, and a-nucleotide loop (Fig. 1)
are available to coordinate or conjugate drugs and analytical
modalities.12 The b-axial ligand is a preferred derivatization site
owing to its ease-of-release in cellular environment and its little
involvement in interaction with proteins. Nitrogen mustard
chlorambucil,13 colchicine,14 cisplatin,15 and insulinomimetic
vanadate (VV) compound16 are drugs which have been bound to
B12 at this site. In addition, fluorophores17 and radionuclides18,19
have also been attached to B12 at this position. The ribose-
hydroxyl group is another convenient derivatization site as it is
not involved in protein interaction.20 Fluorophores,21,22 cytotoxic
drugs,23 insulin,24 and appetite suppressing peptide hPYY25 have
been coupled to B12 via this position.
Derivatization of B12, however, is not limited to the b- and
ribose-positions. Radioactive 111In-DTPA and 99mTc-DTPA were
coupled to B12 via the b-side chain.26,27 The {99mTc(CO)3}
moiety was coupled to B12 via ligands coupled to the b- and
d-side chains28 and biotin via either the b-, c-, d-, or e-side
Fig. 1 Structure of Cyano-cob(III)alamin, vitamin B12 (left) and sketch of
B12 for the following figures.
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chains.12 Increasing structural knowledge of B12 and of its
transport proteins is the base for fine-tuning the structures of
biologically active B12 derivatives and mimetics. Several B12
antagonists were reported, including B12-[c-lactam],29 and B12 with
de novo peptide backbones.30,31 In addition, tissue distribution was
interfered by modifying the B12 structure at a critical site (b-side
chain) for protein interaction.32
Research programs have been dedicated to explore the
correlation of B12 requirements and DNA synthesis. This,
however, is not the only advantage of using B12 as a carrier
for anti-cancer drugs. Its water solubility allows convenient
administration of the attached insoluble drugs.15 B12 protects
protein–peptide drugs24,25,33 from hydrolysis in the acidic condition
of the gastrointestinal track.34 Though the utilization of B12 as
drug carrier appeared to be restrained by its cellular loading
capacity,35 a recent study showed that tissue accumulation of
B12 increased significantly (up to 350%) upon overdosing of the
vitamin.36
In this paper, B12 was applied as a drug carrier for cisplatin
and as a carrier of the {fac-Re(CO)3}
+ moiety, which is a model
moiety for Tc and Re radiopharmaceuticals. Cisplatin was
chosen as it is the most often used platinum based drug in the
clinic, its mode of action is binding to DNA in the nucleus, which
triggers apoptosis and cell death. Cisplatin is taken up by the cells
via passive diﬀusion or via active transport through the copper
transporters (CTR1 and CTR2) and the organic cation transporters
(OCTs) and possible also other pathways.37 Once in the cell cisplatin
undergoes aquation, chloride exchanged by water, forming positive
ions which are more reactive towards the main biological target,
DNA.38 We determined the cytosolic and nucleic uptake of cisplatin,
vitamin B12, [{Co}-CN-{cis-PtCl(NH3)2}]
+ (1), [{Re}-{Co}-CN-{cis-
PtCl(NH3)2}]
+ (2), and [{Co}-CN-{trans-Pt(Cyt)(NH3)2}]
2+ (3) (Fig. 2)
in human leukemia cells (K562 cells) and non-adherent (EATC)/
adherent (ELA) Ehrlich ascites tumor cells. The uptake was deter-
mined by ICP-MS, where the contents of Co, Pt, and Re represent the
uptake of B12 and the platinum/rhenium drug, respectively.
Results and discussion
Synthesis of [{Re}-{Co}-CN-{cis-PtCl(NH3)2}]
+
The tridentate NNO ligand (6) was chelated to the {fac-Re(CO)3}
+
moiety prior to conjugation to the B12 structure (step iv and v,),
see Scheme 1. In the next step, the b-CN was coordinated to
[cis-PtCl(OH2)(NH3)2]
+ by substituting the aquo-ligand bound to
PtII (step vi) to yield 2. This synthesis scheme produced a high
yield (80%) of [{Re}-{Co}-CN-{cis-PtCl(NH3)2}]
+ (2, Scheme 1).
The IR stretching frequency of CN was higher in 2 (2200 cm1)
than in B12 (2134 cm1). It confirmed the formation of {Co}}–CN-
{–{Pt} coordinative bond in 2, as it was previously reported that CN
stretching frequency, bridging two metal centers ({M}}–CN{–{M0}),
appears at higher frequency than terminal CN ({M}}–CN).15,39 The
doubly charged species (m/z 1076.6) on ESI-MS confirmed the
formation of 2 and the NMR spectrum is in agreement with
its authenticity. The single signal in the 195Pt NMR spectrum at
2354 ppm is in the same range as previously reported B12
derivatives containing {Co}–CN{–{Pt} bonds.15,40 Compared to
the 1H NMR spectrum of [{Co}-CN-{PtCl(NH3)2}]
+ previously
published40 the spectrum of [{Re}-{Co}-CN-{cis-PtCl(NH3)2}]
+
shows four additional 1H signals (from the Re-[chelate]-ligand)
in the fingerprint aromatic region45.5 ppm (unmarked peaks
in Fig. 3), which further confirmed the presence of the rhenium
complex.
Aﬃnity of B12 derivatives towards transport proteins
Aﬃnity to transport proteins of B12 derivatives was measured
by Diﬀerential Scanning Fluorometry (DSF), where a fluorescent
dye interacts with the hydrophobic sites of unfolded proteins
and the melting temperature (Tm) of proteins can be inferred
from the recorded fluorescence intensity.41,42 Following ligand
Fig. 2 Structures of B12 derivatives including [{Co}-CN-{cis-PtCl(NH3)2}]
+ (1),
[{Re}-{Co}-CN-{cis-PtCl(NH3)2}]
+ (2), and [{Co}-CN-{trans-Pt(Cyt)(NH3)2}]
2+ (3).
Scheme 1 Synthesis scheme towards [{Re}-{Co}-CN-{cis-PtCl(NH3)2}]
+ (2): (i) Boc2O; (ii) py-2-CHO, NaBH4; (iii) BrCH2CO2Et; (iv) [NEt4]2[ReBr3(CO)3];
(v) TFA and then CDT, TEA; (vi) cisplatin, AgNO3.
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binding, the protein stability is enhanced and the ligand-bound
proteins unfold at higher temperature with respect to the free
proteins. B12 derivatives which bind to B12 transport proteins
would produce comparable DTm values to those of B12 while
DTm values would be much lower if these derivatives do not
bind to B12 transport proteins. In Fig. 4, B12 was used as a
positive control for the three transport proteins and cobinamide
(Cbi) was used as a negative control.42 Despite the chemical
modification of the B12 structure, compound 2 retained good
aﬃnity to all B12 transport proteins as it has comparable DTm
values to those of B12.
Cellular uptake of [{Co}-CN-{cis-PtCl(NH3)2}]
+, [{Re}-{Co}-CN-
{cis-PtCl(NH3)2}]
+ and [{Co}-CN-{trans-Pt(Cyt)(NH3)2}]
2+
To obtain information on the action of these compounds, knowledge
on the amount of drug taken up by cells and accumulated in the
nucleus with and without B12 is required and is the base for
evaluating the eﬃciency of B12 as a tumor-targeting drug carrier
molecule. The metals (Co, Re, Pt) in B12–drugs conjugates can be
measured by ICP-MS, i.e., cytosolic and nucleic determination of
59Co, 195Pt, and 187Re reveal the intracellular distribution of these
compounds. Fig. 5A shows the cellular cisplatin uptake in K562 cells,
determined as the content in the cytosol. The uptake of platinum
containing B12 derivatives (1, 2, and 3) is approximately one third
compared to the uptake of cisplatin. Similarly it is seen from
Fig. 5B that the platinum uptake into cellular nuclei of 1, 2, and
3 was low compared to cisplatin. The low nucleic platinum
uptake of 3 was expected as it has a transplatin-based structure.43,44
More interestingly, substantial extracellular Pt-release from the B12
structures, which would have resulted in comparative cellular
uptake to cisplatin, was not observed. These data indicate that
Pt is not released in the extracellular media but taken up together
with B12. The complexes are protected when conjugated to the B12
structure. Unexpectedly, the cytosolic uptake of B12 was considerably
lower than of [Cbl-OH2]
+, 1, 2, and 3 (Fig. 5). This indicated that the
observed uptake was not mediated by TC as this protein has similar
affinities to B12, 2 (Fig. 4), and 3.42 Therefore TC would have allowed
similar accumulation of these compounds in cellular components.
It was previously reported that B12 derivatives are able to
enter cells without the support of TC. This uptake was, nevertheless,
less eﬃcient.45–48 HeLa cells internalized only 1–2% of free B12
with respect to holo-TC.45 It was later concluded that free B12
supported cell growth ca. 100 to 1000-fold less efficiently than
holo-TC.49 However, human skin fibroblasts could internalize
free B12 better than holo-TC, up to more than 20% were
reported.46 Berliner et al. proposed a free B12-specific receptor
on the cell membrane46 while Hitzig et al. suggested an a2-globulin-
like protein in serum as the alternative pathway for cell to
internalize free B12 derivatives.50
In this study, we observed higher accumulation of [Cbl-OH2]
+ as
compared to B12. In a previous report, it was found that [Cbl-OH2]
+
was internalized and retained better than B12 in human skin
Fig. 3 1H NMR spectrum of [{Re}-{Co}-CN-{cis-PtCl(NH3)2}]
+ (2).
Fig. 4 Binding of B12 and [{Re}-{Co}-CN-{cis-PtCl(NH3)2}]
+ (2) to haptocorrin
(HC), intrinsic factor (IF), and transcobalamin (TC) determined by diﬀerential
scanning fluorometry. High DTm values indicate strong binding.
Fig. 5 Uptake in K562 cellular cytosol (A) and nucleus (B) of [{Co}-CN-{cis-PtCl(NH3)2}]
+ (1), [{Re}-{Co}-CN-{cis-PtCl(NH3)2}]
+ (2), and [{Co}-CN-{trans-
Pt(Cyt)(NH3)2}]
2+ (3). Cisplatin, B12, [Cbl-OH2]
+ were included as control samples.
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fibroblasts culture51 but the root of this diﬀerence was not fully
understood. As we also found comparable cellular uptake among
compounds 1, 2, 3, and [Cbl-OH2]
+, we conclude that the positive
charge carried by these compounds allows cells to internalize
them better than the neutral B12 derivatives (Fig. 5). Behavioral
diﬀerences between charged and neutral B12 derivatives were
also previously observed.52 It is possible that charged B12
compounds were either distinctly recognized by a B12-specific
receptor or they simply passed through the cationic channels on
cell membranes. This, however, requires further clarification. In
any case, the experimental results highlighted once more the
complex multichannel uptake pathways of B12 vitamin analogues
including internalization of holo-TC, free B12 derivatives, and
charged B12 derivatives. The preferable cellular import of charged
B12 compounds should be kept in perspective for future design of
pharmaceutical B12 derivatives.
Drugs like cisplatin and cytarabine attached to the b-CN of
B12 are released by reducing enzymes in the cytosol.15,40,42
Furthermore, subsequent cytotoxic activities of the released
drugs from [{Co}-CN-{cis-PtCl(NH3)2}]
+ (1) and [{Co}-CN-{trans-
Pt(Cyt)(NH3)2}]
2+ (3) were also demonstrated.42,52 Cisplatin
interferes with cell division by binding to DNA. Previous studies
demonstrated accumulation of cisplatin in the cytosol and the
nucleus in non-adherent EATC and adherent ELA cells.53 It is
therefore especially important for compound 1 and 2 to deliver
platinum to nucleus for DNA interaction. As evident from
Fig. 6, platinum accumulated in the nucleus in EATC and in
ELA cells similar to K562 cells. Furthermore, we found that the
absolute amount of platinum bound to DNA in cells exposed for
18 hours to 10 mM and 50 mM [{Re}-{Co}-CN-{cis-PtCl(NH3)2}]
+
(2) was 19 and 83 pmol mg1 DNA (EATC) and 5 and 20 pmol
mg1 DNA (ELA). Hence, cisplatin coupled to B12 derivative did
accumulate in the nucleus and was bound to DNA.
The uptake of Pt into cellular components was always higher
than Co (Fig. 5 and 6). A correlation between cobalt and
platinum uptake for the three compounds 1, 2 and 3 is shown
in Fig. 7. The equation for the trend line is y = 1.60X + 4.9. The
one outlier point for EATC, cytosol was omitted. The correlation
shows that platinum is taken up by a factor of 1.6 higher
than cobalt as estimated from the cytosolic and nucleic content.
This observation could reflect a more eﬃcient eﬄux of Co as
compared to platinum.
Conclusions
We reported here comparable uptake in cellular nuclei and cytosol of
diﬀerent B12–drug conjugates, including [{Co}-CN-{cis-PtCl(NH3)2}]
+,
[{Re}-{Co}-CN-{cis-PtCl(NH3)2}]
+, and [{Co}-CN-{trans-Pt(Cyt)-
(NH3)2}]
2+. The results underline that these B12 derivatives
deliver cispaltin and cisplatin-related drugs to both, cytosol
and nuclei, in two different cancer cell lines. It was found that
charged B12 derivatives were preferentially taken up into cellular
compartments as compared to neutral and native B12. We
therefore propose the existence of an additional uptake pathway
for charged B12 derivatives in addition to the previously known
TC-mediated B12 uptake pathway. Accumulation of released
platinum in the nucleus was clearly observed and explains the
cytotoxic action of these compounds as previously described.50
Experimental
Materials and methods
Analytical high performance liquid chromatography (HPLC)
analyses were performed using a Merck-Hitachi L-7000 system
Fig. 6 Nuclear uptake of [{Co}-CN-{cis-PtCl(NH3)2}]
+ (1), [{Re}-{Co}-CN-{cis-PtCl(NH3)2}]
+ (2), and [{Co}-CN-{trans-Pt(Cyt)(NH3)2}]
2+ (3) in non-adherent
Ehrlich cells (EATC) and adherent Ehrlich Lettre cells (ELA). Uptake was determined as Co, Re, and Pt content in EATC (A) and ELA (B) measured by ICPMS.
Fig. 7 Correlation between drug (Pt) and vitamin B12 (Co) in K562, EATC,
and ELA cells. Uptake was determined as the nuclear (black symbols) and
cytosolic (red symbols) Pt and Co content measured by ICPMS.
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equipped with a diode-array UV/Vis spectrometer. Reaction
progresses to 2, 3, 7 and 8 were monitored by HPLC. Preparative
HPLC purification was performed on Varian Prostar system
with two Prostar 215 pumps and a Prostar 320 UV/Vis detector.
Reaction progresses to 4, 5, and 6 were assessed by TLC. After
purification the B12 derivatives were liophilized. Purity was
assessed by analytical HPLC, IR, ESI-MS (Bruker Daltonic) and
NMR. NMR spectra were recorded by Bruker DRX 500 MHz
spectrometer. Chemical shifts are reported relative to residual
solvent protons and carbons. The chemical shifts of 195Pt NMR
spectra were relative to Na2PtCl6 in D2O.
Phosphate-buﬀered saline (PBS) contained 137 mM NaCl,
2.6 mM KCl, 6.5 mM Na2HPO4, and 1.5 mM KH2PO4. Lysis
buﬀer was prepared from150 mM NaCl, 20 mM HEPES buﬀer,
1 mM EDTA, 0.5% Triton X-100 (Pharmacia Biotech AB),
1% protease inhibitor cocktail (freshly added), 1 mM NaVO3
(freshly added). All aqueous solutions for ICPMS measurement
were prepared in purified water (418.2 MO) from Milli-Q
deionization unit. Standards and samples were prepared in a
mixture of HNO3 0.65% :HCl 0.1%.
HPLC conditions. The analytical HPLC column was Macherey
Nagel Nucleosil C18 (5 mm, 100 Å, 250 mm  3 mm). The
preparative HPLC columnwasMacherey Nagel Nucleosil C18 (7 mm,
100 Å, 250 mm  40 mm) with a flow rate of 35 ml per minute.
The following solvent system was used: 0.1% trifluoroacetic
acid (TFA) (solvent A), methanol (MeOH) (solvent B). The
following solvent gradient was used: gradient 1, 0–5 minutes:
75% A, 5–30 minutes: 0% A.
Syntheses
N-tert-Butyloxycarbonyldiamines (4),54 [NEt4]2[ReBr3(CO)3],
55
and [{Co}-CN-{trans-Pt(Cyt)(NH3)2}]
2+ (3)42 were prepared according
to literature procedures. Compounds (5) and (6) were prepared as
described in literature56 but with the following modifications: 2 g
(4) (11 mmol) was dissolved in 100 ml MeOH. 1.3 g pyridine-2-
carbaldehyde (12 mmol) was added dropwise. After stirring for
3 hours at room temperature, the solvent was removed and the
imine dissolved in 50 ml ethanol (EtOH). Reduction with 1.5 g
NaBH4 in 2 h, removal of solvent, re-dissolution in diluted
NaHCO3 and extraction into CH2Cl2 gave the raw product. The
purification of 5 was performed with silicagel column (ethylacetate,
methanol 1 : 3) (2.8 g, 91%). 1H-NMR (200 MHz, MeOD, d in
ppm): d = 8.63(m, 1H), 7.87(m, 1H), 7.49(m, 1H), 7.41 (m, 1H),
4.37 (s, 2H), 3.32 (m, 2H), 3.29 (m, 2H), 1.94-1.42 (m, 13H).
Rf = 0.28 (NH4OH/methanol/ethylacetate, 1 : 10 : 89). ESI-MS:
m/z = 302.3 [M + H + Na]2+. 1.5 g (5) was mixed with 1 ml
triethylamine in 50 ml EtOH. The mixture was cooled to 0 1C.
600 ml bromo-acetic acid ethylester was added dropwise within
5 min. After stirring for 30 minutes at 0 1C and 16 hours at room
temperature, the solvent was removed in vacuo. The residue was
dissolved in CH2Cl2. Extraction was performed with H2O. The
organic phase was dried over MgSO4, filtered and the solvent
was removed. The product (6) (1.2 g, 60%) was collected as oil.
1H-NMR (200 MHz, MeOD, d in ppm): d = 8.51 (m, 1H), 7.63
(m, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.13 (m, 1H), 4.73 (m, 1H),
4.13 (q, J = 7.2, 7, 7.2 Hz, 2H), 3,89 (s, 2H), 3.36 (s, 2H), 3.06
(d, J = 6 Hz, 2H), 2.65 (t, J = 6.6, 6.8 Hz, 2H), 2.61–1.20 (m, 15H).
ESI-MS: m/z = 366.3 [M + H]+.
4-{Tricarbonylrhenium(I)-[(N,N,O)-(aceticacid)-(pyridine-2-
ylmethyl)amino]} butylcarbamic acid tert-butyl ester (7). 60 mg
(1.5 mmol) NaOH in 1 ml H2O was added to a solution of
176.2 mg (0.48 mmol) of (6) in 2.5 ml MeOH. The reaction
was stirred overnight. The pH was adjusted to 7 with 2 M HCl
and buﬀered with saturated NaHCO3. 374 mg (0.48 mmol)
[NEt4]2[ReBr3(CO)3] in 7 ml MeOH was added. The mixture
was refluxed at 60 1C for 4 h. The product 7 was washed with
water to remove residual NEt4Br to receive the pure product
(235 mg, 80%). 1H-NMR (500 MHz, CD3CN, d in ppm): d = 8.77
(d, J = 5.5 Hz, 1H), 8.02 (t, J = 8.5 Hz, 1H), 7.59 (d, J = 8 Hz, 1H),
7.47 (t, J = 6.5 Hz, 1H), 5.33 (s, 1H), 4.57 (d, J = 16 Hz, 1H), 4.40
(d, J = 15.5 Hz, 1H), 3.70 (d, J = 18 Hz, 1H), 3.56 (m, 2H), 3.32
(d, J = 17 Hz, 1H), 3.08 (m, 2H), 1.81 (m, 2H), 1.48 (m, 2H),
1.4 (s, 13H). IR (KBr, cm1): 2018, 1889, 1872 (CO). ESI-MS:
m/z = 630.3 [M + Na]+.
Synthesis of (8). 50 mg (82.5 mmol) of (7) was Boc deprotected
with 1 ml TFA in 3 ml CH2Cl2. To a solution of 150 mg
(0.11 mmol) B12 in 3.5 ml dry DMSO was added 24 mg
(0.15 mmol) CDT. The mixture was stirred for 1 h at 60 1C.
Then the Boc-deprotected product was added together with 4 ml
dry DMSO and 0.8 ml triethylamine. The reaction was stirred
overnight. Diethyl ether was added to precipitate the product.
Separation of (8) was performed on preparative HPLC, solvent
system 1, gradient 1 (31 mg, 14.5%). 1H-NMR (500 MHz, MeOD,
d in ppm): d = 8.81 (d, J = 5.5 Hz, 1H), 8.07 (m, 1H), 7.71 (t, J = 6.5 Hz,
1H), 7.52 (m, 1H), 7.25 (s, 1H), 7.13 (d, J = 4 Hz, 1H), 6.57 (s, 1H),
6.24 (s, 1H), 5.97 (s, 1H). IR (KBr, cm1): 2136 (CN); 2028, 1918, 1902
(CO). ESI-MS: m/z = 1888 [M + H]+, 945 [M + 2H]2+.
Synthesis of (2). 12 mg (40 mmol) of cisplatin and 6.7 mg
(39 mmol) of AgNO3 were mixed in 1 ml H2O. The reaction was
stirred in the absence of light at 40 1C for 4 h. AgCl was filtered
and the filtrate was added to 22 mg (11.6 mmol) of (8). The
reaction was stirred at 45 1C for one day in the absence of light.
The product was purified by preparative HPLC, solvent system
1, gradient 1 (20 mg, 80%). 1H-NMR (500 MHz, MeOD, d in
ppm): d = 8.80 (d, J = 5 Hz, 1H), 8.08 (d, J = 6 Hz, 1H), 7.72
(m, 1H), 7.54 (m, 1H), 7.25 (s, 1H), 7.14 (s, 1H), 6.58 (s, 1H), 6.26
(s, 1H), 5.99 (s, 1H). 195Pt-NMR (107 MHz, MeOD, d in ppm):
d = 2354. IR (KBr, cm1): 2200 (CN); 2026, 1916, 1904 (CO).
ESI-MS: m/z = 1076.6 [M + 2H]2+.
Aﬃnity to transport proteins
Binding to HC/IF and TC was measured by diﬀerential scanning
fluorimetry (DSF). Details of the method, protein expression and
purification was previously described.42
Uptake measurement with ICPMS. Cells were seeded in T-75
flasks with a seeding density of 3  106 cells per flask. The
culture medium was 12 ml Roswell Park Memorial Institute
(RPMI)-1640 with 10% fetal bovine serum (FCS) and penicillin–
streptomycin (100 U ml1). After 1 day of incubation, each flask
was treated with 10 mM of a compound. These included
cisplatin, B12, [Cbl-OH2]
+, (1), (2), and (3). Cells were further
maintained in culture for two days. Nucleic and cytosolic
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fractions were separated according to a previously published
procedure with certain modifications.53 In details, cells were
centrifuged for 1 minute at 700 g and room temperature (adherent
ELA cells were trypsinized with 0.25% trypsine/EDTA in PBS before
this step). The supernatant was discarded. Pellets were washed
(3) with 5 ml PBS before chemical lysis.57 Lysis buffer was added.
20 ml of the lysate was spared for protein determination (DC
Protein Assay, Bio-Rad). Remaining lysate was centrifuged at
600 g, 4 1C for 5 minutes. The pellet was washed (3) with 1 ml
NaCl/KCl (30 mM/120 mM) solution to isolate nuclei fraction.
The supernatant was centrifuged at 5500 g, 4 1C for 15 minutes.
Cytosolic fraction was the supernatant part. The nuclei fractions
were digested with 100 ml concentrated HNO3.
DNA was isolated according to the following procedure.
Cells were centrifuged two times for 5 s at 13 000–16 000 g.
The precipitate was subsequently lysed with 300 ml lysis
solution. 100 ml of Protein Precipitation Solution was added
andmixed well. After the proteins were precipitated, the supernatant
was transferred into isopropanol (300 ml). This mix is centrifuged for
1 minute at 13000–16000 g to collect DNA as precipitate. The DNA
fractions were washed with 70% ethanol. DNA hydration solution
(50 ml) was then added to the dry DNA. The mixture was then
incubated in a water bath at 65 1C for 1 hour to dissolve DNA,
followed by incubating at room temperature overnight. Both
subcellular fractions were diluted with 0.65% HNO3/0.1% HCl
for ICPMS measurement.
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